Review of Operations Directors’ Report Chairman’s Letter CEO’s Report Financial Report Shareholder Information 30 SIGNIFICANT EVENTS AND TRANSACTIONS CAPITAL RAISE In October 2025, INOVIQ completed a placement to institutional and sophisticated investors, raising $9.5 million (before costs) via 27,142,856 new fully paid ordinary shares in the Company at $0.35 per Share. The pricing of the Placement represented a 15.7% discount to the last traded market price. The Placement was supported by a A$5m cornerstone investment from Tian An Medicare Limited a Hong Kong-listed investment holding company with investments across hospital, healthcare and eldercare in China. That investor is keen to leverage its extensive network across hospitals, clinical laboratories, eldercare and healthcare to support the commercialisation of the EXO-OC screening test in China. On 3 November 2025, INOVIQ announced the completion of the share purchase plan (SPP), with applications totalling $0.7 million accepted, resulting in the issue of 1,999,800 new fully paid ordinary shares. 61 Annual Report 2026
RkJQdWJsaXNoZXIy MjE2NDg3